853297-71-9

Basic information

• Product Name: N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-{4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenyl}-urea
• CAS NO: 853297-71-9
• Molecular Weight: 548.996
• Mol File: 853297-71-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-{4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenyl}-urea(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-{4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenyl}-urea(853297-71-9)
• EPA Substance Registry System: N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-{4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenyl}-urea(853297-71-9)

Safety Data

• Hazardous Substances Data: 853297-71-9(Hazardous Substances Data)

Upstream product

• 100-02-7 4-nitro-phenol 
• 199469-91-5 2-(4-nitro-2-(trifluoromethyl)phenyl)acetic acid 
• 853297-73-1 2-(4-nitro-2-trifluoromethyl-phenyl)-1-(4-ethyl-piperazin-1-yl)-ethanone 
• 124041-03-8 4-chloro-6-(4-nitro-phenoxy)-pyrimidine 
• 105130-28-7 4-(6-Chloropyrimidin-4-yloxy)phenylamine 
• 5308-25-8 4-ethylpiperazine 
• 630125-96-1 4-chloro-6-(4-isocyanato-phenoxy)-pyrimidine 
• 853297-72-0 4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenylamine 

Relevant articles and documents

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.